Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Other financing activities for 7 consecutive years, with $416000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 41.98% to $416000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 5.2% decrease, with the full-year FY2025 number at $1.5 million, down 5.2% from a year prior.
  • Other financing activities was $416000.0 for Q4 2025 at Kymera Therapeutics, down from $419000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $641000.0 in Q3 2024 to a low of -$925000.0 in Q4 2023.
  • A 5-year average of $256250.0 and a median of $299000.0 in 2022 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 222.94% in 2021, then plummeted 403.28% in 2023.
  • Kymera Therapeutics' Other financing activities stood at $156000.0 in 2021, then soared by 95.51% to $305000.0 in 2022, then tumbled by 403.28% to -$925000.0 in 2023, then surged by 131.68% to $293000.0 in 2024, then skyrocketed by 41.98% to $416000.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Other financing activities are $416000.0 (Q4 2025), $419000.0 (Q3 2025), and $382000.0 (Q2 2025).